Itraconazol Stada

Itraconazole, the active ingredient in Itraconazol Stada, is an azole antifungal presented as an oral tablet for oral use. It is indicated for the treatment of a range of systemic and localized fungal infections in adult and pediatric patients under medical supervision.

GNH USA supplies Itraconazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global logistics for qualified healthcare institutions, ensuring timely delivery and regulatory compliance across multiple markets.

Itraconazole is used to treat systemic and localized fungal infections by targeting a broad spectrum of pathogenic fungi.

- Blastomycosis: clears pulmonary and disseminated infection. - Histoplasmosis: resolves acute and chronic disease. - Aspergillosis: treats invasive and allergic forms. - Candidiasis (oropharyngeal and esophageal): eradicates mucosal lesions. - Dermatophytosis: eliminates skin and nail infections. - Sporotrichosis: cures cutaneous and lymphocutaneous disease.

Side effects vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Diarrhea: loose stools, usually self‑limiting. - Abdominal pain: cramping or discomfort. - Rash: mild skin irritation or erythema. - Elevated liver enzymes: mild, often reversible.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, jaundice, or hepatitis. - Congestive heart failure: fluid retention and reduced cardiac function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Visual disturbances: blurred vision or photophobia. - Anaphylaxis: rare systemic allergic reaction.

Before initiating therapy, consider the following precautions.

- Liver function monitoring: assess baseline enzymes and repeat during treatment. - Cardiac assessment: avoid in patients with existing heart failure. - Drug interactions: review concomitant medications for CYP3A4 substrates. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Renal impairment: adjust dose if severe kidney dysfunction is present. - Store below 25°C: keep in the original pack, protect from moisture.

Itraconazole has a notable interaction profile that requires careful management.

Major Interactions (Avoid): - Rifampin: reduces itraconazole plasma levels, compromising efficacy. - St. John’s wort: induces metabolism, leading to subtherapeutic concentrations. - Certain antiarrhythmics (e.g., amiodarone): may cause serious cardiac effects.

Moderate Interactions (Monitor Closely): - Statins (e.g., simvastatin): increased risk of myopathy. - Benzodiazepines (e.g., midazolam): enhanced sedation. - Proton pump inhibitors: may decrease absorption of itraconazole.